期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Pioneer of prostate cancer: past, present and the future of FOXA1 被引量:14
1
作者 mona teng Stanley Zhou +2 位作者 Changmeng Cai Mathieu Lupien Housheng Hansen He 《Protein & Cell》 SCIE CAS CSCD 2021年第1期29-38,共10页
Prostate cancer is the most commonly diagnosed noncutaneous cancers in North American men.While androgen deprivation has remained as the cornerstone of prostate cancer treatment,resistance ensues leading to lethal dis... Prostate cancer is the most commonly diagnosed noncutaneous cancers in North American men.While androgen deprivation has remained as the cornerstone of prostate cancer treatment,resistance ensues leading to lethal disease.Forkhead box A1(FOXA1)encodes a pioneer factor that induces open chromatin conformation to allow the binding of other transcription factors.Through direct interactions with the Androgen Receptor(AR),FOXA1 helps to shape AR signaling that drives the growth and survival of normal prostate and prostate cancer cells.FOXA1 also possesses an AR-independent role of regulating epithelial-to-mesenchymal transition(EMT).In prostate cancer,mutations converge onto the coding sequence and c/s-regulatory elements(CREs)of FOXA1,leading to functional alterations.In addition,FOXA1 activity in prostate cancer can be modulated post-translationally through various mechanisms such as LSD1-mediated protein demethylation.In this review,we describe the latest discoveries related to the function and regulation of FOXA1 in prostate cancer,pointing to their relevance to guide future clinical interventions. 展开更多
关键词 FOXA1 CANCER alterations
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部